MRSN - Mersana Therapeutics, Inc.
29.08
0.040 0.138%
Share volume: 712,460
Last Updated: 01-05-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.14%
PREVIOUS CLOSE
CHG
CHG%
$29.04
0.04
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-09-2024 | 08-13-2024 | 11-13-2024 | 03-03-2025 | 05-15-2025 | 08-13-2025 | 11-14-2025 | |
| Assets | ||||||||
| Total Assets | 198.373 M | 179.128 M | 169.530 M | 144.663 M | 112.471 M | 84.573 M | 62.686 M | |
| Current Assets | 187.538 M | 168.963 M | 160.557 M | 136.904 M | 106.188 M | 80.141 M | 59.988 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 107.960 M | 103.744 M | 76.303 M | 26.870 M | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 75.186 M | 58.998 M | 78.868 M | 107.750 M | 102.287 M | 76.972 M | 56.391 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 3.408 M | 0.000 | 0.000 | 0.000 | 1.887 M | 1.037 M | 163.000 K | |
| Other Assets | 7.427 M | 10.165 M | 8.973 M | 7.759 M | 4.396 M | 3.395 M | 2.535 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 198.373 M | 179.128 M | 169.530 M | 144.663 M | 112.471 M | 84.573 M | 62.686 M | |
| Total liabilities | 170.388 M | 170.701 M | 168.481 M | 154.172 M | 143.339 M | 137.719 M | 122.223 M | |
| Total current liabilities | 53.406 M | 62.184 M | 68.301 M | 62.458 M | 58.161 M | 59.338 M | 43.269 M | |
| Accounts Payable | 3.086 M | 3.013 M | 2.033 M | 4.330 M | 4.374 M | 2.923 M | 2.393 M | |
| Other liabilities | 4.862 M | 3.897 M | 2.316 M | 1.300 M | 262.000 K | 0.000 | 0.000 | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 20.098 M | 17.049 M | 13.999 M | 10.950 M | 7.901 M | 0.000 | 0.000 | |
| Other liabilities | 4.862 M | 3.897 M | 2.316 M | 1.300 M | 262.000 K | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 27.985 M | 8.427 M | 1.049 M | -9.509 M | -30.868 M | -53.146 M | -59.537 M | |
| Common stock | 873.742 M | 878.433 M | 882.460 M | 886.034 M | 888.808 M | 890.826 M | 891.980 M | |
| Retained earnings | -845.667 M | -869.935 M | -881.436 M | -895.553 M | -919.676 M | -943.972 M | -951.517 M |